Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors. The study is designed to assess clinical efficacy and safety, building on a strong synergistic rationale and promising early-phase data.

NCT Number	NCT07712029
Lead Sponsor	Tianjin Medical University Second Hospital Collaborators: Lepu Biopharma Co., Ltd.
Conditions	Advanced Refractory Solid Tumors, EGFR Gene Overexpression
Enrollment	32 participants
Start Date	2026-08-01
Primary Completion	2028-08-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-17